State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements

Silwal, A., Talbert, J., Bohler, R. M., Kelsch, J., Cook, C., Blevins, D., Gallivan, M., Hunt, T., Hatcher, S. M., Thomas, C. P., Williams, S., Fanucchi, L., & Lofwall, M. R. (2023). State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements. Drug and Alcohol Dependence Reports, 7, 100164. https://doi.org/10.1016/j.dadr.2023.100164

Authors:

Anita Silwal

Jeffery Talbert

Robert M Bohler

Jordan Kelsch

Christopher Cook

Derek Blevins

Molly Gallivan

Timothy Hunt

Sarah M Hatcher

Cindy Parks Thomas

Soncere Williams

Laura Fanucchi

Michelle R Lofwall

Affiliated Authors:

Derek Blevins

Columbia Affiliation:

Vagelos College of Physicians and Surgeons
- Department of Psychiatry
  Division of Substance Use Disorders

Author Keywords:

buprenorphine

data waiver

opioid use disorder treatment

policy

treatment barriers

elink

Publication Type:

Article

Unique ID:

10.1016/j.dadr.2023.100164

PMID:

37234704

DOI:

10.1016/j.dadr.2023.100164

Journal:

Drug and Alcohol Dependence Reports

Publication Date:

2023-06-01

Data Source:

PubMed

Source Link:

View PubMed Record

Record Created:

Monday, August 12, 2024 - 11:03